With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

The targeted drug release device TAR-200 shows promising response and disease-free survival rates in specific populations of ...

Johnson & Johnson (JNJ) posts promising Phase 2b trial results for its chemotherapy releasing system TAR-200 in bladder ...